Fundraising Fox
🦊/Companies
Sign in

Immitra Bio

Zürich, CH · Founded 2024 · 6 employees on LinkedIn · 8 known investors

Find your way into Immitra Bio

172 people in our graph share verified history with the Immitra Bio team — schools, employers, funds. One of them is your warm intro.

Bastian Hasslingerunlockedknows Jan Nelis · together at ETH Zürich (overlapped)
×4knows the team · via Princeton University
×6knows the team · via ETH Zürich
knows the team · via Immitra Bio

Immitra Bio develops an in-vivo stem cell therapy platform designed to treat rare genetic diseases, particularly severe inherited red blood cell disorders, by replacing complex transplants with single off-the-shelf treatments. The company is an ETH Zürich spin-off focused on precision medicine and gene editing approaches for genetic disease intervention.

BiotechDeep TechMedical Devices

Founders & leadership

JNJan Nelis
Jan NelisinCEOJan Nelis is co-founder and CEO of Immitra Bio, an ETH Zürich spin-off developing stem cell therapies for genetic blood disorders. He holds a degree in Molecular Health Science from ETH Zürich and has background in rowing and sports.

Investors · 8

Kickfund✓ verifiedZurich · $950K
OCCIDENT✓ verifiedMunich
another.vc✓ verifiedMülheim an der Ruhr · $270K
Backbone Ventures✓ verifiedZurich · $330K – $440K
Venture Kick✓ verifiedSchlieren-Zürich

Also in the syndicate · 3

ETH FoundationFONGITZürcher Kantonalbank

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Immitra Bio raises CHF 2.4 million for in-vivo gene editing | GGBaggba.swiss · Aug 2026Zürich-based Immitra Bio secures €2.58 million to scale its scalable in-vivo genetic medicine platform | EU-Startupseu-startups.com · Jul 2026Immitra Bio Closed a CHF 2.4 Million Pre-Seed Financing Round - BioAlpsbioalps.org · Jul 2026Immitra Bio raises CHF 2.4M for in-vivo gene editing - European Biotechnology Magazineeuropean-biotechnology.com · Jul 2026Immitra Bio Secures CHF 2.4M / USD 3M in Pre-Seed Fundingimmitrabio.com · Jul 2026Immitra Bio Receives a CHF 150,000 Gebert Rüf Stiftung InnoBooster Grant - BioAlpsbioalps.org · May 2026

Frequently asked questions

What does Immitra Bio do?
Immitra Bio develops an in-vivo stem cell therapy platform designed to treat rare genetic diseases, particularly severe inherited red blood cell disorders, by replacing complex transplants with single off-the-shelf treatments. The company is an ETH Zürich spin-off focused on precision medicine and gene editing approaches for genetic disease intervention.
Who are Immitra Bio's investors?
Immitra Bio's investors include Kickfund, OCCIDENT, another.vc, Backbone Ventures, Venture Kick.
Where is Immitra Bio headquartered?
Immitra Bio is headquartered in Zürich, CH.